Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
Abstract Background: To evaluate consecutively the cognitive function of a chronic mouse model of Parkinson’s disease (PD) induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine/probenecid (MPTP/p) in different modeling periods, and to study the characteristics of cognitive decline in PD and its molecular mechanism. Methods: In this study, we used MPTP and probenecid to induce a chronic PD mouse model, the Y-maze test to evaluate the cognitive function of the model in different modeling periods, western blotting (WB) to quantify phosphorylated alpha-synuclein (p-α-syn), Toll-like receptors (TLRs), Nod-like receptors (NLRs), Choline acetyltransferase (ChAT), glial fibrillary acidic protein (GFAP), p62, Interleukin-1β (IL-1β) and other related indicators, immunohistochemical staining (IHC) to characterize the expression of p-α-syn, immunofluorescence staining (IF) to observe the co-localization of p-α-syn and cholinergic neurons (ChAT+) or astroglias (GFAP+) in the hippocampus. The TLR2 inhibitor CU-CPT22 was used to intervene in the subacute MPTP PD mouse model and then the expression of TLR2, ChAT, GFAP, p62 and IL-1β were evaluated again. Results: In the Y-maze test after 1/2/3/4/5 weeks of administration, the percentage of bouts to the Novel arm and the percentage of duration in the Novel arm of the MPTP/p group mice were lower than those of the Saline group mice, and there were statistical differences at the second week. At the same time, the p-α-syn monomer in the hippocampus of chronic MPTP/p PD mice increased, accompanied by the increase of GFAP, TLR2, Nuclear factor-κB (NF-κB), NLR pyrin domain containing 3 (NLRP3), p62 and IL-1β, and the decrease of the ratio of LC3Ⅱ to LC3I (LC3Ⅱ/I). The p-α-syn in the hippocampus increased, and co-localized significantly with GFAP and slightly with ChAT. TLR2 inhibitor CU-CPT22 can reduce the expression of GFAP, p62 and IL-1β in the subacute MPTP mouse model. Conclusion: Autophagy inhibition and inflammation activation induced by p-α-syn through TLR2 pathway in the hippocampus of MPTP mouse model of Parkinson’s disease contribute to its cognitive function decline in the early stage, indicating the potential of TLR2 as a therapeutic target for PD cognitive decline.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.